You are here

Gilead purchase of novel cancer treatment raises cost issues again

A potential replay of the Sovaldi scandal is further complicated by the way the treatment is administered

Washington

GILEAD Sciences' acquisition of Kite Pharma has brought it back to a familiar - and contentious - dilemma: How much should a drugmaker charge for a novel drug that has the potential to cure a disease?

Back in 2013, Gilead was battered by public outrage when it priced its

sentifi.com

Market voices on:

Powered by GET.comGetCom